A Novel Treatment for Malarial Infections

The inventions described herein are antimalarial small molecule inhibitors of the plasmodial surface anion channel (PSAC), an essential nutrient acquisition ion channel expressed on human erythrocytes infected with malaria parasites. These inhibitors were discovered by high-throughput screening of chemical libraries and analysis of their ability to kill malaria parasites in culture. Two separate classes of inhibitors were found to work synergistically in combination against PSAC and killed malaria cultures at markedly lower concentrations than separately. These inhibitors have high affinity and specificity for PSAC and have acceptable cytotoxicity profiles. Preliminary in vivo testing of these compounds in a mouse malaria model is currently ongoing.

Potential Commercial Applications: Competitive Advantages:
Treatment of malarial infections  
  • Novel drug treatment for malarial infections
  • Synergistic effect of these compounds on PSAC

Sanjay Desai (NIAID)

Intellectual Property:
PCT Application No. PCT/US09/50637
US Application No. 61/083,000
US Application No. 13/055,104

Kang M, et al. PMID 15843600
Desai SA, et al. PMID 10984055

Collaboration Opportunity:

The NIAID Office of Technology Development is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize antimalarial drugs that target PSAC or other parasite-specific transporters. Please contact Dana Hsu at 301-496-2644 for more information.

Licensing Contact:
Kevin Chang , Ph.D.
NIH Office of Technology Transfer
Email: changke@mail.nih.gov
Phone: 301-435-5018

OTT Reference No: E-202-2008/0

Updated: Feb-13-2012